Clinical Trials · NCT03987074
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Gilead Sciences
- Enrollment
- 109
- Start date
- Jul 2019
- Locations
- 18 sites, United States
- Primary endpoint
- Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)